Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2024-01-11 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
东莞证券关于特一药业使用2023年度以简易程序向特定对象发行股票部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the use of idle raised funds from a 2023 private placement stock issuance by Te Yi Pharmaceutical Group Co., Ltd. It discusses the approval process, regulatory compliance, and the intended temporary use of idle funds to supplement working capital. The document references regulatory guidelines and approvals but does not contain financial statements or quarterly/yearly financial results. It is a formal verification or audit opinion related to the use of funds raised through a capital issuance. This fits best under the category of Audit Report / Information (AR), as it is a standalone audit/verification report on the use of raised funds, not an annual report, earnings release, or capital update announcement. The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement or report publication notice. Therefore, the classification is AR with high confidence. FY 2023
2024-01-11 Chinese
关于第五届董事会第十八次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by 特一药业集团股份有限公司, detailing the approval of a proposal to use idle raised funds temporarily to supplement working capital. It includes meeting details, voting results, and references another announcement on the same topic. The document is short (990 characters) and serves as a notification of a board decision rather than a full report or financial statement. It does not contain financial statements or detailed financial data. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2024-01-11 Chinese
关于使用2023年度以简易程序向特定对象发行股票部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of idle raised funds from a specific stock issuance in 2023 to temporarily supplement working capital. It details the approval by the board and supervisory committee, references regulatory approvals, and explains the purpose and safeguards of the fund usage. The document is relatively short (3260 characters) and does not contain financial statements or detailed financial data. It is an update on capital usage related to fundraising activities, specifically the use of proceeds from a private placement of shares. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or audit report. It is not a report publication announcement since it contains substantive information about the use of funds, not just a notice of report availability.
2024-01-11 Chinese
关于第五届监事会第十七次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of a resolution passed at the 17th meeting of the 5th Supervisory Board of the company. It discusses approval for the temporary use of idle raised funds from a specific stock issuance to supplement working capital. The document is short (810 characters) and is a formal announcement of a board decision rather than a detailed financial report or audit. It does not contain financial statements or detailed financial data. It is not a full report but a regulatory announcement of a board resolution related to capital use. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-01-11 Chinese
关于提前归还可转债部分暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the early repayment of part of the funds temporarily used from convertible bond proceeds to supplement working capital. It details the board resolution, amounts involved, and repayment status. The document is short (902 characters) and focuses on a specific financing activity related to convertible bonds and the use of raised funds. It does not contain financial statements or comprehensive financial data, nor is it a full report. It is clearly an update on capital/financing activities, specifically about the use and repayment of raised funds. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-01-05 Chinese
国浩律师（深圳）事务所关于特一药业集团股份有限公司2023年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality of procedures and voting results of a company's 2023 second extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. It does not contain financial statements or management discussion but focuses on the legality and validity of the shareholder meeting and its resolutions. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes and related shareholder meeting details.
2023-12-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.